



55300691

CONFIDENTIAL

## BRACAnalysis CDx® Genetic Test Result

## FDA Approved BRCA1 and BRCA2 Analysis Result

BRACAnalysis CDx®

Germline Companion Diagnostic Test

RECEIVING HEALTHCARE PROVIDER	SPECIMEN	PATIENT
Test HCP, MD Test Medical Center 6609 BLANCO RD STE 200 SAN ANTONIO, TX 78216	Specimen Type: Blood Draw Date: Apr 20, 2023 Accession Date: Apr 20, 2023 Report Date: Apr 20, 2023	Legal Name: Pt Last Name, Pt First Name Date of Birth: Apr 20, 1978 Patient ID: Patient id Sex at Birth: F Accession #: 07007717-BLD Requisition #: 47073858

**GENETIC RESULT: POSITIVE - CLINICALLY SIGNIFICANT MUTATION IDENTIFIED**

Note: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated with the potential to alter medical intervention.

GENE	MUTATION	INTERPRETATION
BRCA1	c.68_69del (p.Glu23Valfs*17) Heterozygous	DELETERIOUS

**ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED****ADDITIONAL INFORMATION**

Genes Analyzed: Unless otherwise noted sequencing and large rearrangement analyses were performed on the following genes:

BRCA1, BRCA2

**Intended Use:** BRACAnalysis CDx® is an *in vitro* diagnostic device intended for the qualitative detection and classification of variants in the protein-coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR.

Results of the test are used as an aid in identifying patients who are or may become eligible for treatment with the targeted therapies listed in Table 1 in accordance with the most recently approved therapeutic product labeling.

Table 1. Companion Diagnostic Indications

Tumor Type	Biomarker	Therapy
Breast Cancer	Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes	Lynparza® (olaparib)
		Talzenna® (talazoparib)
Ovarian Cancer	Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes	Lynparza® (olaparib)
		Zejula® (niraparib)
Pancreatic Cancer	Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes	Lynparza® (olaparib)
Prostate Cancer	Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes	Lynparza® (olaparib)



## BRACAnalysis CDx<sup>®</sup> Genetic Test Result

Name: Pt Last Name, Pt First Name

DOB: Apr 20, 1978

Accession #: 07007717-BLD

Report Date: Apr 20, 2023

This assay is for professional use only and is to be performed only at Myriad Genetic Laboratories, a single laboratory site located at 320 Wakara Way, Salt Lake City, UT 84108.

### Contraindication:

- Patients who have undergone a previous allogeneic bone marrow transplant should not be tested with the BRACAnalysis CDx<sup>®</sup> test.

### Limitations:

- Patients under consideration for testing who have been diagnosed with a hematologic malignancy, such as leukemia, could generate a positive (deleterious or suspected deleterious) result that is somatic, and not germline, due to chromosome instability.
- The classification and interpretation of all variants identified reflects the current state of scientific understanding at the time the result report is issued. In some instances, the classification and interpretation of variants may change as scientific information becomes available.
- Limitation: In Ovarian Cancer, ~70% of tumor *BRCA1* or *BRCA2* mutation positive patients are estimated to have a germline mutation while ~30% of patients are estimated to have a somatic mutation. In Prostate Cancer, ~50% of tumor *BRCA1* or *BRCA2* mutation positive patients are estimated to have a germline mutation while ~50% of patients are estimated to have a somatic mutation. The BRACAnalysis CDx test detects germline mutations only, not somatic mutations from patient's blood sample. A negative result using the BRACAnalysis CDx blood test in ovarian and prostate cancer patients does not rule out the possibility of a somatic *BRCA1* or *BRCA2* mutation in tumor tissue from these patients.

For more detailed information, including a complete list of Contraindications, Limitations, Warnings and Precautions of the assay, please see page 2 of the BRACAnalysis CDx<sup>®</sup> Technical Information at: <https://s3.amazonaws.com/myriad-web/BRACAnalysisCDxTS.pdf>

The majority of deleterious or suspected deleterious mutations identified by Myriad in *BRCA1* and *BRCA2* are classified using objective criteria based on the type and genomic position of the mutations. Other deleterious or suspected deleterious mutations may be classified by other criteria that are based on available evidence. Myriad's myVision<sup>®</sup> Variant Classification Program performs ongoing evaluations of variant classifications. In certain cases, the healthcare provider may be contacted for more clinical information or to arrange family testing to aid in variant classification. When new evidence about a variant is identified and determined to result in clinical significance and management changes, that information will automatically be made available to the healthcare provider through an amended report. If you have any questions or concerns about how the variant(s) in this result were classified, please contact Myriad.

Please contact Myriad at 1-800-469-7423 with any questions or feedback regarding services provided.

This Authorized Signature  
pertains to this laboratory report:

Benjamin B. Roa, PhD  
Diplomate ABMG  
Laboratory Director

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. It is strongly recommended that these test results be communicated to the patient in a setting that includes appropriate counseling. This test was developed and its performance characteristics determined by Myriad Genetic Laboratories. Myriad is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.



## BRACAnalysis CDx<sup>®</sup> Genetic Test Result

Name: Pt Last Name, Pt First Name

DOB: Apr 20, 1978

Accession #: 07007717-BLD

Report Date: Apr 20, 2023

*The following information has not been reviewed and approved by the FDA. This assay identifies patients at risk for Hereditary Breast and Ovarian Cancer (HBOC) syndrome associated with deleterious or suspected deleterious BRCA1 or BRCA2 variants. Additional information is provided for hereditary cancer management purposes.*

**DETAILS ABOUT: BRCA1 c.68\_69del (p.Glu23Valfs\*17): NM\_007294.3; (aka: 185delAG, 187delAG)**

**Functional Significance: Deleterious - Abnormal Protein Production and/or Function**

The heterozygous germline *BRCA1* mutation c.68\_69del is predicted to result in the premature truncation of the *BRCA1* protein at amino acid position 39 (p.Glu23Valfs\*17).

**Clinical Significance: High Risk**

If this individual is of Ashkenazi Jewish ancestry, it is recommended that follow-up testing of relatives of this individual include analysis for the mutations c.68\_69del (p.Glu23Valfs\*17) and c.5266dupC (p.Gln1756Profs\*74) in *BRCA1* and c.5946del (p.Ser1982Argfs\*22) in *BRCA2* because of reports of coexistence of two high-frequency germline mutations in some Ashkenazi families (Ramus SJ et al. Nature Genetics 1997. 15:14-15). This mutation is associated with increased cancer risk and should be regarded as clinically significant.

### ADDITIONAL TREATMENT INFORMATION

This assay is intended to be used as an aid in treatment decision making for the PARP inhibitors Lynparza<sup>®</sup> (olaparib), Zejula<sup>®</sup> (niraparib) and Talzenna<sup>®</sup> (talazoparib). Full prescription information for Lynparza<sup>®</sup> (olaparib) is available at: [http://www.azpicentral.com/Lynparza/pi\\_lynparza.pdf](http://www.azpicentral.com/Lynparza/pi_lynparza.pdf). Full prescription information for Zejula<sup>®</sup> (niraparib) is available at: [https://gskpro.com/content/dam/global/hcpportal/en\\_US/Prescribing\\_Information/Zejula\\_Capsules/pdf/ZEJULA-CAPSULES-PI-PIL.PDF](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Zejula_Capsules/pdf/ZEJULA-CAPSULES-PI-PIL.PDF). Full prescription information for Talzenna<sup>®</sup> (talazoparib) is available at: <http://labeling.pfizer.com/ShowLabeling.aspx?id=11046>. For more detailed information including Performance Characteristics, please find the complete Technical Information at: <https://myriad.com/technical-specifications>.

### ASSOCIATED CANCER RISKS AND CLINICAL MANAGEMENT

If a clinically significant mutation is identified, please see the management tool associated with this report for a summary of cancer risk and professional society medical management guidelines that may be useful in developing a plan for this patient. Testing of other family members may assist in the interpretation of this patient's test result.

### DETAILS ABOUT NON-CLINICALLY SIGNIFICANT VARIANTS

All individuals carry DNA changes (i.e., variants), and most variants do not increase an individual's risk of cancer or other diseases. When identified, variants of uncertain significance (VUS) are reported. Likely benign variants (Favor Polymorphisms) and benign variants (Polymorphisms) are not reported and available data indicate that these variants most likely do not cause increased cancer risk. Present evidence does not suggest that non-clinically significant variant findings be used to modify patient medical management beyond what is indicated by the personal and family history and any other clinically significant findings.



Myriad Genetics Laboratories, Inc.  
320 Wakara Way  
Salt Lake City, Utah 84108  
PH: +1 (877) 283-6709  
FX: +1 (801) 883-8998  
[www.myriad.com](http://www.myriad.com)

#### Outside U.S.A

Email: [CustomerSupport@myriadgenetics.eu](mailto:CustomerSupport@myriadgenetics.eu)



Myriad International GmbH  
Nattermannallee 1  
50829 Cologne, Germany



The Myriad Genetics BRACAnalysis CDx<sup>®</sup> test was developed and performance characteristics were determined by Myriad Genetic Laboratories, Inc. and in compliance to In-Vitro Diagnostic Device Directive (98/79/EC) and is CE marked. Myriad is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing. Myriad is compliant with multiple international standards including, ISO13485:2016 and ISO 15189: 2012 as applicable.

Sex assigned at birth refers to the classification of an individual as male or female, often based on physical characteristics at birth.



55300691

CONFIDENTIAL

Management Tool - BRACAnalysis CDx®

# BRCA1 and BRCA2 Analysis

BRACAnalysis CDx®

Germline Companion Diagnostic Test

**RECEIVING HEALTHCARE PROVIDER**

Test HCP, MD  
 Test Medical Center  
 6609 BLANCO RD STE 200  
 SAN ANTONIO, TX 78216

**SPECIMEN**

Specimen Type: Blood  
 Draw Date: Apr 20, 2023  
 Accession Date: Apr 20, 2023  
 Report Date: Apr 20, 2023

**PATIENT**

Legal Name: Pt Last Name,  
 Pt First Name  
 Date of Birth: Apr 20, 1978  
 Patient ID: Patient id  
 Sex at Birth: F  
 Accession #: 07007717-BLD  
 Requisition #: 47073858

**GENETIC RESULT: POSITIVE - CLINICALLY SIGNIFICANT MUTATION IDENTIFIED**

Note: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated with the potential to alter medical intervention.

GENE	MUTATION	THIS GENETIC TEST RESULT IS ASSOCIATED WITH THE FOLLOWING CANCER RISKS:
<i>BRCA1</i>	c.68_69del (p.Glu23Valfs*17) Heterozygous	HIGH RISK: Breast, Ovarian ELEVATED RISK: Pancreatic

Please see the Genetic Test Result for more details on any variant(s) detected in this patient, including variant classification information.

The terms "male", "female", "he", "she", "women", and "men" refer to sex assigned at birth.

**ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED**

## CLINICAL OVERVIEW OF GENETIC FINDINGS

### Hereditary Breast and Ovarian Cancer syndrome (HBOC)

- This patient has been found to have a mutation in the *BRCA1* gene. Individuals with mutations in *BRCA1* have Hereditary Breast and Ovarian Cancer syndrome (HBOC).
- Women with HBOC have a risk for breast cancer that is greatly increased over the 12.5% lifetime risk for women in the general population of the United States. Most breast cancers in women with *BRCA1* mutations are Triple Negative Breast Cancer (TNBC), a type of breast cancer lacking estrogen and progesterone receptors, and not expressing Her2.
- Women with HBOC also have high risks for ovarian, fallopian tube, and primary peritoneal cancer.
- Men with HBOC due to mutations in *BRCA1* have an elevated risk for breast and prostate cancer. The increased risk for prostate cancer may be most significant at younger ages. Additionally, men with a *BRCA1* mutation have a higher risk for an aggressive prostate cancer.
- Male and female patients with HBOC due to mutations in *BRCA1* have an elevated risk for exocrine pancreatic cancer. These are cancers developing in the enzyme-secreting cells of the pancreas.
- Some studies have found that women with *BRCA1* mutations have an increased risk for uterine cancer, but other studies have found no increased risk. There are currently no medical management recommendations for uterine cancer risk in women with mutations in *BRCA1*. If hysterectomy is considered, there is the option for hormone replacement therapy (HRT) with estrogen alone, which is associated with a lower risk of breast cancer than HRT with estrogen and progesterone.
- Although there are high cancer risks for patients with HBOC, there are interventions that have been shown to be effective at reducing many of these risks. Guidelines from the National Comprehensive Cancer Network (NCCN) for the medical management of patients with HBOC are listed below. It is recommended that patients with *BRCA1* mutations and a diagnosis of HBOC be managed by a multidisciplinary team with experience in the prevention and treatment of the cancers associated with HBOC.



© 2023 Myriad Genetics, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615

The format and contents of this report are proprietary and may not be copied or used without permission, except for purposes of diagnosis, counseling, and treating the patient identified in the report and members of their family. Myriad, BRACAnalysis CDx, myVision, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions. Lynparza is a registered trademark of AstraZeneca group of companies. Zejula is a registered trademark of GSK. Talzenna is a registered trademark of Pfizer, Inc.



## Management Tool - BRCAAnalysis CDx®

Name: Pt Last Name, Pt First Name

DOB: Apr 20, 1978

Accession #: 07007717-BLD

Report Date: Apr 20, 2023

### WHAT ARE THE PATIENT'S CANCER RISKS?

The risk table or tables that follow show the clinically significant cancer risks identified as part of this patient's testing. The risk for each gene result is provided separately. If the risk for any individual cancer is affected by more than one of these results, the risk associated with each finding is listed in a separate table. At this time, there is not enough information to estimate risks for cancers affected by more than one gene mutation, or risks based on both gene mutations and personal/family history.

The cancer risks in the table(s) below are estimates based on the best data currently available in the published literature. Risks for individual patients may be significantly higher or lower depending on personal and family history and the presence or absence of other risk factors.

#### Risks Due to Hereditary Breast and Ovarian Cancer syndrome (HBOC)

CANCER TYPE	CANCER RISK	RISK FOR GENERAL POPULATION	RELATED TO
<b>FEMALE BREAST</b>			
To age 50	28%-51%	2.0%	BRCA1
To age 70	46%-87%	7.4%	BRCA1
Second primary within 5 years of first breast cancer diagnosis	8.9%-20%	2%	BRCA1
<b>OVARIAN</b>			
To age 50	8%-23%	0.2%	BRCA1
To age 70	39%-63%	0.6%	BRCA1
Ovarian cancer within 10 years of a breast cancer diagnosis	12.7%	<1.0%	BRCA1
<b>PANCREATIC</b>			
To age 80	Elevated risk	1.1%	BRCA1

### WHAT MANAGEMENT FOR CANCER RISKS SHOULD BE CONSIDERED?

This overview of clinical management guidelines is based on the patient's genetic test results. Medical management guidelines are summarized from established medical societies, primarily the National Comprehensive Cancer Network (NCCN). If there are overlapping management guidelines for any individual cancer due to more than one gene result, the guidelines associated with each finding are listed in separate tables, even if they are the same. At this time, there are no medical society guidelines for how to adjust management when there are multiple sources of risk, such as from more than one gene mutation. In these cases, it may be appropriate to use the most aggressive management option provided.

The overview provided below should not be used as the sole source of information to determine medical management. The references cited should always be consulted for more details and updates to the recommendations.

No information is provided related to treatment of a previous or existing cancer or polyps. The recommendation summaries below may require modification due to the patient's personal medical history, past surgeries and other treatments. Patients with a past history of cancer, benign tumors, or pre-cancerous findings may be candidates for long term surveillance and risk-reduction strategies beyond what is necessary for the treatment of their initial diagnosis. Any discussion of medical management options is for general information purposes only and does not constitute a recommendation. While genetic testing and medical society recommendations provide important and useful information, medical management decisions should be made in consultation between each patient and their healthcare provider.

**Management Tool - BRACAnalysis CDx<sup>®</sup>**

Name: Pt Last Name, Pt First Name

DOB: Apr 20, 1978

Accession #: 07007717-BLD

Report Date: Apr 20, 2023

**Management Options for Hereditary Breast and Ovarian Cancer syndrome (HBOC)**

PROCEDURE	AGE TO BEGIN	FREQUENCY Unless otherwise indicated by findings	RELATED TO
<b>FEMALE BREAST</b>			
Breast awareness - Women should be familiar with their breasts and promptly report changes to their healthcare provider. Periodic, consistent breast self-examination (BSE) may facilitate breast awareness. <sup>2</sup>	18 years	NA	BRCA1
Clinical breast examination <sup>2</sup>	25 years	Every 6 to 12 months	BRCA1
Breast MRI with contrast and/or mammography with consideration of tomosynthesis <sup>2</sup>	Age 25 for MRI, or if MRI is unavailable, mammography with consideration of tomosynthesis. Age 30 for both MRI and mammography. Individualize to a younger age if a relative has been diagnosed younger than age 30.	Annually	BRCA1
Consider investigational screening studies within clinical trials. <sup>2</sup>	Individualized	NA	BRCA1
Consider risk-reducing mastectomy. <sup>2</sup>	Individualized	NA	BRCA1
Consider options for breast cancer risk-reduction agents (i.e. tamoxifen). <sup>2</sup>	Individualized	NA	BRCA1
<b>OVARIAN</b>			
Bilateral salpingo-oophorectomy <sup>2</sup>	35 to 40 years, upon completion of childbearing	NA	BRCA1
Consider transvaginal ultrasound and CA-125 measurement. Consider investigational screening studies within clinical trials. <sup>2</sup>	30 to 35 years	Individualized	BRCA1
Consider options for ovarian cancer risk-reduction agents (i.e. oral contraceptives). <sup>2,5</sup>	Individualized	NA	BRCA1
<b>PANCREATIC</b>			
For patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in screening for pancreatic cancer, preferably within research protocols. <sup>3</sup>	Age 50, or 10 years younger than the earliest age of pancreatic cancer diagnosis in the family	Annually	BRCA1
Provide education about ways to reduce pancreatic cancer risk, such as not smoking and losing weight. <sup>6</sup>	Individualized	Individualized	BRCA1



## Management Tool - BRACAnalysis CDx<sup>®</sup>

Name: Pt Last Name, Pt First Name

DOB: Apr 20, 1978

Accession #: 07007717-BLD

Report Date: Apr 20, 2023

### Management Options for Hereditary Breast and Ovarian Cancer syndrome (HBOC)

PROCEDURE	AGE TO BEGIN	FREQUENCY Unless otherwise indicated by findings	RELATED TO
-----------	--------------	---	------------

#### FOR PATIENTS WITH A CANCER DIAGNOSIS

For patients with a gene mutation and a diagnosis of cancer, targeted therapies may be available as a treatment option for certain tumor types (e.g., platinum chemotherapy, PARP-inhibitors)<sup>1,4,6,7,8</sup>

NA

NA

BRCA1

1. Armstrong DK, et al. NCCN Clinical Practice Guidelines in Oncology<sup>®</sup>: Ovarian Cancer. V 1.2021. Feb 26. Available at <https://www.nccn.org>.
2. Daly M et al. NCCN Clinical Practice Guidelines in Oncology<sup>®</sup>: Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic. V 1.2022. Aug 11. Available at <https://www.nccn.org>.
3. Goggins M, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020 69:7-17. PMID: 31672839.
4. Gradishar WJ et al. NCCN Clinical Practice Guidelines in Oncology<sup>®</sup>: Breast Cancer. V 5.2021. June 28. Available at <https://www.nccn.org>.
5. Gupta S, et al. NCCN Clinical Practice Guidelines in Oncology<sup>®</sup> Genetic/Familial High-Risk Assessment: Colorectal. V 1.2021. May 11. Available at <https://www.nccn.org>.
6. Tempero MA, et al. NCCN Clinical Practice Guidelines in Oncology<sup>®</sup>: Pancreatic Adenocarcinoma. V 2.2021. Feb 25. Available at <https://www.nccn.org>.
7. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/209115s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdf)
8. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/208558s002lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s002lbl.pdf)

#### Notes for Personalized Management:

### INFORMATION ON HOW CANCER RISKS AND MANAGEMENT ARE DETERMINED

The Management Tool provides cancer risk levels and management recommendations based on analysis of the genetic results (see Genetic Result). Additional details and references for cancer risks and management recommendations can be found on [myriadmyrisk.com/genetable/](http://myriadmyrisk.com/genetable/).

- A comprehensive risk assessment may include other aspects of the patient's personal/family medical history, as well as lifestyle, environment and other factors.
- No management recommendations are provided related to treatment of a previous or existing cancer or polyps. The recommendations provided may require modification based on the patient's personal medical history, surgeries and other treatments. Patients with a personal history of cancer, benign tumors or pre-cancerous findings may be candidates for long term surveillance and risk-reduction strategies beyond what is necessary for the treatment of their initial diagnosis.
- Patients who have a clinical diagnosis of a genetic cancer syndrome (e.g., Lynch syndrome) may have different management recommendations than provided. Management should be personalized based on all known clinical diagnoses.
- The Genetic Test Result Summary includes: female breast, male breast, colorectal, endometrial, gastric, ovarian, pancreatic and prostate cancers, and melanoma. In this summary a gene associated cancer risk is described as "High Risk" for a cancer type if all of the following conditions are met: the absolute risk of cancer is approximately 5% or higher, the increase in risk over the general population is approximately 2 to 3-fold or higher, and there is significant data from multiple studies supporting the cancer risk estimate. A gene is described as "Elevated Risk" for a cancer type if there is sufficient data to support an increase in cancer risk over the general population risk, but not all criteria for "High Risk" are met.







## Management Tool - BRCAAnalysis CDx®

Name: Pt Last Name, Pt First Name

DOB: Apr 20, 1978

Accession #: 07007717-BLD

Report Date: Apr 20, 2023

### INFORMATION FOR FAMILY MEMBERS

Family members should talk to their healthcare providers about hereditary cancer testing to help define their own risk and assist in the interpretation of this patient's genetic test result.

- This patient's relatives are at risk for carrying the same mutation(s) and associated cancer risks as this patient. Cancer risks for individuals who have this/these mutation(s) are provided below.
- **Family members should talk to a healthcare provider about genetic testing.** Close relatives such as parents, children, and siblings have the highest chance of having the same mutation(s) as this patient. Other more distant relatives such as cousins, parents siblings, and grandparents also have a chance for carrying the same mutation(s). Testing of at-risk relatives can identify those family members with the same mutation(s) who may benefit from surveillance and early intervention. More resources for family testing are available at MySupport360.com.

### Additional Information for Hereditary Breast and Ovarian Cancer syndrome (HBOC)

- In rare instances, an individual may inherit mutations in both copies of the *BRCA1* gene, leading to the condition Fanconi Anemia, Complementation Group S (FANCS). This condition is rare and may include physical abnormalities, developmental delay, and a high risk for cancer. The children of this patient are at risk of inheriting FANCS only if the other parent is also a carrier of a *BRCA1* mutation. Screening the other biological parent of any children for *BRCA1* mutations may be appropriate.
- Parents who are concerned about the possibility of passing on a *BRCA1* mutation to a future child may want to discuss options for prenatal testing and assisted reproduction techniques, such as pre-implantation genetic diagnosis (PGD).

### CANCER RISK FOR *BRCA1* CLINICALLY SIGNIFICANT MUTATION

CANCER TYPE	CANCER RISK	RISK FOR GENERAL POPULATION
FEMALES		
<b>FEMALE BREAST</b>		
To age 50	28%-51%	2.0%
To age 70	46%-87%	7.4%
Second primary within 5 years of first breast cancer diagnosis	8.9%-20%	2%
<b>OVARIAN</b>		
To age 50	8%-23%	0.2%
To age 70	39%-63%	0.6%
Ovarian cancer within 10 years of a breast cancer diagnosis	12.7%	<1.0%
MALES		
<b>PROSTATE</b>		
To age 70	Up to 16%	6.1%
<b>MALE BREAST</b>		
To age 70	1.2%	<0.1%
FEMALES AND MALES		
<b>PANCREATIC</b>		
To age 80	Elevated risk	1.1%





## Management Tool - BRACAnalysis CDx<sup>®</sup>

Name: Pt Last Name, Pt First Name

DOB: Apr 20, 1978

Accession #: 07007717-BLD

Report Date: Apr 20, 2023

Please contact Myriad at 1-800-469-7423 with any questions or feedback regarding services provided.

END OF MANAGEMENT TOOL